FDA Approves Higher Dose of Biogen Genetic Disorder Drug
The FDA has approved a higher-dose version of Biogen's drug for a rare genetic disorder. The new regimen will be available to U.S. patients in the coming weeks.
Xurve View
Insights:
Xurve View
The United States Food and Drug Administration has approved a higher-dose version of a treatment for a rare genetic disorder that causes progressive muscle weakness, according to an announcement by Biogen Inc. on Monday. The approval provides a new therapeutic path for patients after the regulator previously declined the application last year due to a need for further technical data.
